Joseph V Manetta

US Patent:

8183346, May 22, 2012

Filed:

Dec 1, 2009

Appl. No.:

12/628263

Inventors:

Donmienne Doen Mun Leung - San Diego CA, US
Peng Luan - Livermore CA, US
Joseph Vincent Manetta - Indianapolis IN, US
Ying Tang - San Diego CA, US
Derrick Ryan Witcher - Fishers IN, US

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

C07K 16/00
C07K 16/28
C07K 16/46

US Classification:

5303871, 5303873, 5303879, 5303882

Abstract:

Provided are monoclonal antibodies and antigen-binding fragments thereof that bind to, and inhibit the activity of human FPN1, and which are effective in maintaining or increasing the transport of iron out of mammalian cells and/or maintaining or increasing the level of serum iron, reticulocyte count, red blood cell count, hemoglobin, and/or hematocrit in a subject in vivo.

US Patent:

20050075488, Apr 7, 2005

Filed:

Jul 18, 2002

Appl. No.:

10/484280

Inventors:

Stuart Bright - Carmel IN, US
Audrey Jia - Union City CA, US
Stuart Kuhstoss - Indianapolis IN, US
Joseph Vincent Manetta - Indianapolis IN, US
Naoya Tsurushita - Palo Alto CA, US
Maximiliano Vasquez - Palo Alto CA, US

International Classification:

C07K016/24

US Classification:

530388150, 530388230

Abstract:

The present invention encompasses high affinity antibodies that neutralize IL-1β activity in vivo. These antibodies can be used to treat various diseases such as rheumatoid arthritis and osteoarthritis.

US Patent:

20060233788, Oct 19, 2006

Filed:

Sep 2, 2004

Appl. No.:

10/568467

Inventors:

Mark Heiman - Indianapolis IN, US
Kristine Kikly - Fortville IN, US
Joseph Manetta - Indianapolis IN, US
Derrick Witcher - Fishers IN, US

International Classification:

A61K 39/395

US Classification:

424133100, 530388100

Abstract:

Monoclonal antibodies, including humanized and chimeric antibodies, that bind acylated and unacylated human ghrelin are provided. Such monoclonal antibodies can be full-length, or an antigen-binding portion thereof, and are useful for neutralizing ghrelin activity, e.g., in a human subject suffering from a disorder in which ghrelin activity is detrimental.

US Patent:

20070237775, Oct 11, 2007

Filed:

Jul 6, 2005

Appl. No.:

11/569769

Inventors:

Kristine Kikly - Fortville IN, US
Joseph Manetta - Indianapolis IN, US
Derrick Witcher - Fishers IN, US

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

A61K 39/395
C07K 16/26

US Classification:

424141100, 530388100

Abstract:

Monoclonal antibodies, including chimeric and humanized antibodies, that bind both acylated and unacylated human ghrelin are disclosed. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Such antibodies and antigen-binding portions thereof are useful for neutralizing ghrelin activity in, for example, a human subject suffering from a disorder in which ghrelin activity is detrimental.

US Patent:

20090060920, Mar 5, 2009

Filed:

Nov 8, 2005

Appl. No.:

11/577530

Inventors:

Derrick Ryan Witcher - Fishers IN, US
Kristine Kay Kikly - Fortville IN, US
Joseph Vincent Manetta - Indianapolis IN, US

International Classification:

A61K 39/395
C07K 16/26
A61P 3/04
A61P 3/10

US Classification:

4241451, 5303881

Abstract:

A neutralizing epitope is identified within amino acids 1-3 of desacyl ghrelin. Antibodies that bind this epitope fall within the scope of the invention and can be murine, chimeric, or humanized antibodies, immunoconjugates of the antibodies, or antigen-binding fragments thereof. The antibodies of the invention are useful for the treatment or prevention of obesity and related disorders including, for example, Type II non-insulin dependent diabetes mellitus (NIDDM), Prader-Willi syndrome, eating disorders, hyperphagia, and impaired satiety. Additionally, such antibodies can be useful for the treatment or prevention of other disorders, including anxiety, gastric motility disorders (including e.g., irritable bowel syndrome and functional dyspepsia), insulin resistance syndrome, metabolic syndrome, dyslipidemia, atherosclerosis, hypertension, hyperandrogenism, polycystic ovarian syndrome, cancer, and cardiovascular disorders by administering a therapeutically effective amount of an anti-desacyl ghrelin monoclonal antibody of the invention.

US Patent:

20130122013, May 16, 2013

Filed:

May 7, 2012

Appl. No.:

13/465462

Inventors:

Donmienne Doen Mun LEUNG - San Diego CA, US
Peng LUAN - Livermore CA, US
Joseph Vincent MANETTA - Indianapolis IN, US
Ying TANG - San Diego CA, US
Derrick Ryan WITCHER - Fishers IN, US

Assignee:

ELI LILLY AND COMPANY - Indianapolis IN

International Classification:

C07K 16/28
A61K 38/18
A61K 39/395

US Classification:

4241431, 536 2353, 4353201, 435326, 435 696

Abstract:

Provided are monoclonal antibodies and antigen-binding fragments thereof that bind to, and inhibit the activity of human FPN1, and which are effective in maintaining or increasing the transport of iron out of mammalian cells and/or maintaining or increasing the level of serum iron, reticulocyte count, red blood cell count, hemoglobin, and/or hematocrit in a subject in vivo.

US Patent:

49239678, May 8, 1990

Filed:

Sep 26, 1988

Appl. No.:

7/248757

Inventors:

Jesse L. Bobbitt - Indianapolis IN
Joseph Manetta - Indianapolis IN

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

C07K 324
C07K 1506
C07K 740
C07K 1300

US Classification:

530351

Abstract:

The present invention discloses a new method for solubilizing and refolding recombinant proteins expressed as granules. The method involves sulfitolysis and the formation of a precipitate of protein-S-sulfonate by warming. The precipitate has been found to contain protein in high purity. In addition, proper folding takes place if the desired protein is fully reduced and passed through an intermediate concentration of denaturant which allows for a transition between its folded and unfolded states.

US Patent:

52350398, Aug 10, 1993

Filed:

Jun 10, 1991

Appl. No.:

7/712828

Inventors:

William F. Heath - Indianapolis IN
Mei-Huei T. Lai - Carmel IN
Joseph V. Manetta - Indianapolis IN
John R. Sportsman - Indianapolis IN

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

A61K 3702
C07K 500
C12Q 170
C12Q 137

US Classification:

530328

Abstract:

An assay method for the rapid determination of hydrolytic enzyme activity in large numbers of samples is provided which comprises bonding a resin-binding compound, such as biotin, to one side of the scissile bond of the substrate and a reporter molecule, such as a fluorescence marker, to the opposite side of the scissile bond, incubating the modified substrate and the enzyme in multiple well plates, e. g. 96-well plates, optionally in the presence if a test inhibitor or activator compound transferring the incubation solutions to a second multiple well plate having upper and lower chambers separated by a porous membrane the upper chamber of which contains resin beads capable of binding with the resin-binding compound, filtering and washing the wells of the second plate and reading the emission from the plates. The invention also provides protease substrates for HIV-1 protease, vertebrate stromelysin and derivatives thereof which are useful in the assay method.